1. Home
  2. Category
  3. Treatment Types

Targeted Therapies

Article

Prediction of Adverse Events in Patients Receiving Rapid Rituximab Infusion

Dora Siew Ping Lang
Chiew Cheng Fong
CJON 2014, 18(1), 89-92 DOI: 10.1188/14.CJON.89-92
Rapid rituximab infusion was approved as treatment for non-Hodgkin lymphoma by the U.S. Food and Drug Administration in 2012, but it has been administered clinically since approval of the drug rituximab in 1997. Because of the delay between the approval of the drug and the approval of the procedure...
0
No votes yet
Read this Article
Article

Issues Related to Overadherence to Oral Chemotherapy or Targeted Agents

Sandra L. Spoelstra
Barbara A. Given
Charles W. Given
Marcia Grant
Alla Sikorskii
Mei You
Veronica Decker
CJON 2013, 17(6), 604-609 DOI: 10.1188/13.CJON.17-06AP
Use of oral chemotherapy or targeted agents is shifting how cancer treatment is administered, moving it from supervised office visits to self-administration at home. This study examines issues related to overadherence to oral agents that were noted during a trial conducted by the authors comparing...
0
No votes yet
Read this Article
Online Exclusive Article

Nursing Perspectives on Trastuzumab Emtansine for the Treatment of Metastatic Breast Cancer

Laura Bourdeanu
Thehang Luu
CJON 2013, 17(5), E58-E62 DOI: 10.1188/13.CJON.E58-E62
Increased understanding of the molecular composition of breast cancer tumors has led to the development of targeted anticancer agents. Novel therapies directed against human epidermal growth factor receptor 2 (HER2) in breast cancer have been developed. One such agent, trastuzumab emtansine (T-DM1...
0
No votes yet
Read this Article
Article

Ruxolitinib: A New Treatment for Myelofibrosis

Emily W. Lowery
Susan M. Schneider
CJON 2013, 17(3), 312-318 DOI: 10.1188/13.CJON.312-318
Myelofibrosis (MF) is a blood cancer characterized by fibrotic bone marrow and altered hematopoiesis. Although the prevalence of MF is low, its severe symptoms have a significantly negative impact on patient quality of life, and its ability to transform into leukemia increases morbidity...
0
No votes yet
Read this Article
Online Exclusive Article

Carfilzomib: A Next-Generation Proteasome Inhibitor for Multiple Myeloma Treatment

Elizabeth Bilotti
CJON 2013, 17(2), E35-E44 DOI: 10.1188/13.CJON.E35-E44
Although the incidence of multiple myeloma (MM) is increasing, the median overall survival and the number of agents in the pipeline for treating MM also are increasing. Response rates higher than 80% are not uncommon in the frontline setting when the novel agents thalidomide, lenalidomide, and...
0
No votes yet
Read this Article

Questions, Concerns or Requests

We're just a click away for assistance.